Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabien Despas

Showing results (31-40 of 89) with videos related to

Pageof 9
Sort By:
Therapie|October 1, 2014
[Cetuximab cutaneous adverse drug reactions: a marker of efficacy for metastatic colorectal cancer and head-neck cancer?]Marlène Soussan-Dahan, Maryse Lapeyre-Mestre, Emmanuelle Bondon-Guitton, et al.
Plos One|November 23, 2013
Acute electromyostimulation decreases muscle sympathetic nerve activity in patients with advanced chronic heart failure (EMSICA Study)Marc Labrunée, Fabien Despas, Philippe Marque, et al.
Therapie|July 10, 2016
[Not Available]Jordan Birebent, Julie Dupouy, Michel Bismuth, et al.
Acute Cardiac Care|November 26, 2009
Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recordingFabien Despas, Charlotte Trouillet, Nicolas Franchitto, et al.
Pharmacoepidemiology and Drug Safety|February 16, 2017
Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance databaseAurore Palmaro, Marie-Eve Rougé-Bugat, Martin Gauthier, et al.
Therapie|November 4, 2018
What is pharmacoepidemiology? Definition, methods, interest and clinical applicationsJean-Louis Montastruc, Justine Benevent, François Montastruc, et al.
British Journal of Clinical Pharmacology|June 27, 2018
Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBaseJulien Mahé, Emilie Patras de Campaigno, Anne-Laure Chené, et al.
Leukemia & Lymphoma|May 15, 2024
Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposureFabien Despas, Maria Chaouki, Sandra de Barros, et al.
Therapie|March 3, 2019
The value of a health insurance database to conduct pharmacoepidemiological studies in oncologyCécile Conte, Charlotte Vaysse, Pauline Bosco, et al.
British Journal of Clinical Pharmacology|October 26, 2022
Incidence of heart failure following exposure to a protein kinase inhibitor, a French population-based studyYoann Zelmat, Cécile Conte, Pernelle Noize, et al.
Pageof 9

Showing results (31-40 of 89) with videos related to

Sort By:
Pageof 9
Therapie|October 1, 2014
[Cetuximab cutaneous adverse drug reactions: a marker of efficacy for metastatic colorectal cancer and head-neck cancer?]Marlène Soussan-Dahan, Maryse Lapeyre-Mestre, Emmanuelle Bondon-Guitton, et al.
Plos One|November 23, 2013
Acute electromyostimulation decreases muscle sympathetic nerve activity in patients with advanced chronic heart failure (EMSICA Study)Marc Labrunée, Fabien Despas, Philippe Marque, et al.
Therapie|July 10, 2016
[Not Available]Jordan Birebent, Julie Dupouy, Michel Bismuth, et al.
Acute Cardiac Care|November 26, 2009
Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recordingFabien Despas, Charlotte Trouillet, Nicolas Franchitto, et al.
Pharmacoepidemiology and Drug Safety|February 16, 2017
Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance databaseAurore Palmaro, Marie-Eve Rougé-Bugat, Martin Gauthier, et al.
Therapie|November 4, 2018
What is pharmacoepidemiology? Definition, methods, interest and clinical applicationsJean-Louis Montastruc, Justine Benevent, François Montastruc, et al.
British Journal of Clinical Pharmacology|June 27, 2018
Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBaseJulien Mahé, Emilie Patras de Campaigno, Anne-Laure Chené, et al.
Leukemia & Lymphoma|May 15, 2024
Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposureFabien Despas, Maria Chaouki, Sandra de Barros, et al.
Therapie|March 3, 2019
The value of a health insurance database to conduct pharmacoepidemiological studies in oncologyCécile Conte, Charlotte Vaysse, Pauline Bosco, et al.
British Journal of Clinical Pharmacology|October 26, 2022
Incidence of heart failure following exposure to a protein kinase inhibitor, a French population-based studyYoann Zelmat, Cécile Conte, Pernelle Noize, et al.
Pageof 9